Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

DOI Full Paper Access

600

Citations

36

References

2009

Year

Gerhardt Attard, Alison Reid, Roger A’Hern, Christopher Parker, Nikhil Babu Oommen, Elizabeth Folkerd, Christina Messiou, L. Rhoda Molife, Gal Maier, Emilda Thompson,

Journal of Clinical Oncology

Abstract

CYP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven.

References

	Year	Citations

Page 1